


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199716</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-8976</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Viral immunology</Title>
                <ISOAbbreviation>Viral Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>HPV18 E1 Protein Plus <i>α</i>-Galactosylceramide Elicit in Mice CD8<sup>+</sup> T Cell Cross-Reactivity Against Cells Expressing E1 from Diverse Human Papillomavirus Types.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1089/vim.2019.0020</ELocationID>
            <Abstract>
                <AbstractText>CD8<sup>+</sup> T cell immune response plays a critical role in the clearance of human papillomavirus (HPV)-infected cells. During the natural history of HPV infection, the E1 protein, an early-expressed helicase highly conserved among papillomaviruses, is involved in the replication of HPV genomes. We have previously shown, in a murine model, that immunization with HPV18 E1 protein combined with <i>α</i>-galactosylceramide elicits a specific CD8<sup>+</sup> T cell response. We further proved those findings by analyzing whether CD8<sup>+</sup> T cells from mice immunized with <i>α</i>-galactosylceramide plus HPV18 E1 protein could have a cytotoxic effect on cells expressing the carboxyl-terminal domain from the E1 proteins of other HPV types. Interestingly, CD8<sup>+</sup> T cells raised against HPV18 E1 antigen presented cross-reactivity against the E1 protein from HPV53, 33, 16, and 31. Poor cross-reactivity was observed for HPV11, and none for HPV6. This outcome may be relevant for the design of broad-spectrum immune-protective agents against HPV infections.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Amador-Molina</LastName>
                    <ForeName>Alfredo</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Tlalpan, México.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amador-Molina</LastName>
                    <ForeName>Juan C</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>2 Tecnológico de Monterrey, Departamento de Bioingeniería, Campus Estado de México, Estado de México, México.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arciniega</LastName>
                    <ForeName>Juan L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>3 Biologics Consulting (Affiliate), Department of Pharmaceuticals and Biologics, Alexandria, Virginia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lizano</LastName>
                    <ForeName>Marcela</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Tlalpan, México.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>4 Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Viral Immunol</MedlineTA>
            <NlmUniqueID>8801552</NlmUniqueID>
            <ISSNLinking>0882-8245</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">-galactosylceramide</Keyword>
            <Keyword MajorTopicYN="N">CD8 T cells</Keyword>
            <Keyword MajorTopicYN="N">E1 protein</Keyword>
            <Keyword MajorTopicYN="N">cross-reactivity</Keyword>
            <Keyword MajorTopicYN="N">human papillomavirus</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199716</ArticleId>
            <ArticleId IdType="doi">10.1089/vim.2019.0020</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

